The same market valued it at over 60c with far less achieved at one point. What was that valuation based on, I ask?
Tomorrow, if there was a popular narrative that highlighted Imugene as a poster child for American cancer research and innovation, licenced to an Australian company that was floundering on the ASX, while Chinese biotech competitors were ploughing ahead. Well then, there might certainly be an argument that the company's valuation might be completely different if rumours of a NASDAQ listing persisted.
Heck, the presence of some here preaching in the desert might even be taken as evidence of foreign interference by some bad actors.
But yea, for what it's worth, I would love to know what Trump might actually say about the whole situation. And I would think it naive not to believe that biotech is a matter of national pride or security for some countries, and Imugene's interests might be better served on the NASDAQ.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)